share_log

Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate

Benzinga ·  Feb 14 16:16

Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. The company reported quarterly sales of $22.93 million which beat the analyst consensus estimate of $21.75 million by 5.47 percent. This is a 12.73 percent decrease over sales of $26.28 million the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment